Gradientech closes fully subscribed USD 4.6million rights issue to progress QuickMIC™ diagnostic system for ultra-rapid AST testing

Uppsala, Sweden, April 4, 2019. Swedish biotechnology company Gradientech today announced it has closed a fully subscribed rights issue totalling USD 4.6 million (SEK 42.5 million).Existing owners, as well as new parties appointed by Erik Penser Bank AB, who acted as financial advisor, have subscribed. Bird & Bird Lawyers acted as legal advisors.

Dr Sara Thorslund, CEO of Gradientech says: “We have now successfully completed Gradientech’s largest rights issue, which provides capital for continued development and early market introduction of our QuickMIC™ diagnostic system. Our system is significantly faster than existing laboratory techniques for antibiotic resistance testing of samples from sepsis patients. This is critically important for the sepsis patient, and also advantageousfor the healthcare economy since the length of stay in hospital can be reduced. The implementation of our QuickMIC system can also reduce improper use of antibiotics, which is very import to combat the global increase in antibiotic resistance.”

New shareowners include a noticeable number of individuals with solid industrial experience from the diagnostics field, and also persons experienced specifically within the area of antibiotic susceptibility testing.

“We are particularly pleased that, in addition to new investment capital, people with very relevant business backgrounds and important networks have joined the ownership structure. I believe this will benefit the company’s development strongly going forward,” concludes Sara Thorslund.

For further information, please contact:
Sara Thorslund, PhD, CEO Gradientech
Tel: +46 736 29 35 80

Gradientech is an ISO13485 certified company since 2017


Gradientech AB
Uppsala Science Park
SE-751 83 Uppsala


About Gradientech

Gradientech develops, manufactures and sells innovative microfluidic products for high-quality analysis of the behavior of cells and organisms in response to gradients of biomolecules. Our aim is to pioneer life science and healthcare.

Copyright © 2024 Gradientech. All rights reserved. Gradientech, QuickMIC and CellDirector are registered trademarks or trademarks of Gradientech AB.

Next-generation antimicrobial susceptibility testing

Take a look at our E-book